current
statu
challeng
rna
interfer
rnai
microrna
modul
strategi
treatment
myocardi
disord
discuss
relat
classic
gene
therapeut
approach
past
decad
section
summar
key
issu
current
vector
technolog
determin
may
suitabl
clinic
translat
experiment
chapter
discuss
current
statu
challeng
use
rna
interfer
rnai
microrna
modul
strategi
treatment
myocardi
disord
relat
classic
gene
therapeut
approach
past
decad
introductori
sect
summar
key
issu
current
vector
technolog
critic
determin
may
suitabl
clinic
translat
experiment
rnai
microrna
therapeut
protocol
present
discuss
two
exampl
deal
potenti
cardiac
rnai
therapi
first
exampl
deal
attempt
block
earli
step
pathogenesi
virusinduc
cardiomyopathi
result
heart
failur
rnai
target
cellular
receptor
cardiopathogen
virus
sect
second
exampl
deal
approach
improv
cardiac
function
rnai
target
late
common
pathway
heart
failur
pathogenesi
common
myocardi
disord
multipl
etiolog
strategi
direct
myocardiac
ca
homeostasi
major
compon
heart
failur
due
coronari
heart
diseas
ischem
cardiomyopathi
heart
valv
dysfunct
valvular
cardio
moypathi
cardiac
inflamm
inflammatori
cardiomyopathi
genet
defect
dilat
cardiomyopathi
sect
wherea
first
type
strategi
direct
earli
pathogen
step
need
tailormad
differ
type
pathogenesi
second
type
target
late
common
pathway
much
broader
rang
applic
advantag
second
type
approach
major
import
sinc
enorm
effort
need
undertaken
rnai
micro
rnabas
therapeut
protocol
enter
stage
possibl
clinic
translat
number
patient
elig
protocol
larg
actual
transform
experiment
therapi
new
therapeut
option
major
clinic
import
far
like
occur
classic
first
concept
gene
therapi
develop
monogen
disord
caus
defici
singl
gene
gene
substitut
therapi
field
cardiolog
sever
monogen
disord
primarili
manifest
myocardium
could
theoret
cure
approach
among
variou
longqt
syndrom
arrhythmogen
right
ventricular
dysplasia
brugada
syndrom
hypertroph
cardiomyopathi
caus
host
mutat
variou
sarcomer
protein
dilat
cardiomyopathi
second
concept
gene
therapi
enhanc
gene
function
cell
tissu
organ
overexpress
primarili
endogen
gene
use
gene
transfer
vector
appropri
condit
therapeut
effect
may
achiev
genet
determin
also
acquir
diseas
third
concept
addit
truli
novel
gene
function
target
organ
vectorbas
express
foreign
gene
novel
concept
far
recent
origin
involv
use
nonproteincod
small
regulatori
rna
molecul
therapeut
purpos
includ
fourth
concept
short
hairpin
rna
transcript
vector
suppress
gene
function
diseas
target
organ
organ
via
mechan
rna
interfer
fifth
concept
use
microrna
gener
vector
achiev
therapeut
modul
cell
organ
function
level
cellular
microrna
system
see
part
book
natur
follow
key
issu
classic
gene
therapi
concept
also
appli
similarli
rnabas
therapi
concept
figur
illustr
fundament
differ
action
classic
gene
therapi
vs
rna
therapi
time
point
import
partial
overlap
two
otherwis
distinct
strategi
common
need
deliv
therapeut
structur
cdnaencod
protein
vs
regulatori
rna
right
place
appropri
concentr
suffici
period
time
adequ
safeti
featur
partial
overlap
allow
exploit
advanc
vector
technolog
initi
develop
gene
therapi
field
type
rna
therapi
first
key
issu
vector
technolog
mere
physic
steer
target
vector
irrespect
express
proteinencod
cdna
short
hairpin
rna
premicrorna
target
tissu
eg
myocardium
prove
difficult
task
variou
approach
hoshijima
et
al
rockman
et
al
white
et
al
kypson
et
al
koch
et
al
ikeda
et
al
includ
intracoronari
applic
giordano
et
al
mauric
et
al
employ
achiev
goal
includ
alreadi
clinic
trial
alitalo
simon
et
al
grine
et
al
hedman
et
al
better
understand
molecular
cellular
determin
vector
target
cardiovascular
system
evolv
past
year
base
studi
express
pattern
vector
receptor
ie
receptor
primarili
mediat
cellular
uptak
viru
vector
deriv
anim
fechner
et
al
fechner
et
al
human
noutsia
et
al
poller
et
al
b
discoveri
anatom
barrier
vascular
endothelium
intracellular
matrix
fechner
et
al
inhibit
prevent
vector
transfer
particular
part
heart
organ
tumor
interestingli
express
particularli
import
vector
receptor
coxsackieviru
adenovirusreceptor
car
found
highli
variabl
human
heart
gener
induct
dilat
cardiomyopathi
noutsia
et
al
commun
et
al
anim
local
induct
myocardi
infarct
fechner
et
al
receptordirect
strategi
curiel
improv
myocardi
vector
target
evalu
without
signific
success
vivo
perfect
physic
vector
target
diseas
tissu
achiev
addit
transcript
confin
transgen
may
achiev
use
cardiacspecif
promotor
franz
et
al
henderson
et
al
reynold
et
al
recognit
strong
receptordepend
vector
target
prompt
investig
deal
possibl
therapeut
potenti
tropism
modif
alter
receptorinteract
domain
virus
use
vector
number
studi
vectorsuscept
differ
primari
cell
type
tropism
modif
conduct
adenovir
wickham
wickham
et
al
aav
vector
nicklin
baker
rabinowitz
et
al
ponnazhagan
et
al
ponnazhagan
hoover
shi
bartlett
perabo
et
al
et
al
basic
approach
employ
alter
viral
surfac
structur
mediat
cellular
receptor
bind
intern
vector
achiev
genet
engin
vector
gene
encod
vector
surfac
compon
ogorelkova
et
al
poller
et
al
bifunct
antibodi
bind
vector
surfac
epitop
cellular
structur
specif
desir
target
cell
noutsia
et
al
bispecif
target
protein
conjug
vector
surfac
via
avidinbiotin
complex
perabo
al
howev
none
approach
achiev
similar
success
vivo
recent
gener
pseudotyp
aav
vector
particular
cardiac
target
although
use
vector
may
combin
tropism
optim
introduc
addit
alter
pseudotyp
aav
capsid
tissuespecif
promot
emphas
order
tropism
modif
becom
use
vivo
vector
first
need
get
direct
access
desir
target
cell
may
prevent
howev
anatom
barrier
vascular
endothelium
basal
membran
extracellular
matrix
addit
studi
address
receptor
issu
number
approach
overcom
anatom
barrier
evalu
vale
et
al
boeksteg
et
al
beeri
et
al
davidson
et
al
price
et
al
donahu
et
al
hajjar
et
al
none
method
simpl
yet
appropri
applic
clinic
set
myocardi
gene
therapi
final
target
cell
beyond
anatom
barrier
particularli
difficult
target
compar
cell
type
current
state
art
viral
vector
option
achiev
transfer
rate
suffici
therapeut
efficaci
far
report
success
vivo
treatment
cardiac
diseas
use
nonvir
system
includ
nanoparticl
publish
given
obstacl
effici
target
vector
deliveri
recent
develop
imag
techniqu
vivo
detect
transgen
express
may
greatli
facilit
develop
monitor
assess
cardiac
gene
therapeut
procedur
wu
et
al
inubushi
et
al
auricchio
et
al
second
key
issu
vector
technolog
stabil
transgen
function
transgen
protein
express
short
hairpin
premicrorna
transcript
genet
therapi
heart
failur
meant
serv
bridgetotranspl
bridgetorecoveri
longterm
stabil
therapeut
vector
plu
transgen
requir
among
virusbas
vector
system
use
myocardi
gene
transfer
current
promis
system
achiev
longterm
stabil
deriv
adenoassoci
virus
aav
aav
vector
although
still
difficult
produc
high
titer
need
vivo
applic
shown
stabil
year
fulli
immunocompet
hemophil
dog
treat
intramuscularli
coagul
factor
ixproduc
aav
vector
monahan
et
al
herzog
et
al
base
experiment
data
factor
ix
aav
vector
evalu
clinic
phase
trial
kay
et
al
high
stabil
appear
consequ
inher
fundament
biolog
properti
aav
genom
afion
et
al
although
alway
clear
whether
transgen
express
occur
integr
episom
vector
genom
sequenc
vectorgenom
junction
demonstr
presenc
integr
aav
genom
cultur
human
cell
mice
treatment
aav
vector
miller
et
al
rutledg
russel
nakai
et
al
nakai
et
al
nakai
et
al
aav
vector
recent
employ
cardiac
genet
treatment
heart
failur
hoshijima
et
al
system
treatment
fabri
diseas
takahashi
et
al
substitut
gene
therapi
inherit
cardiomyopathi
due
gene
defect
kawada
et
al
transgen
express
sever
month
case
third
key
vector
technolog
paramount
import
clinic
applic
may
consid
safeti
gene
transfer
protocol
one
safeti
featur
intens
investig
approach
toward
regul
transgen
inject
host
may
requir
applic
necessari
situat
adapt
transgen
activ
physiolog
requir
level
desir
option
shut
transgen
complet
time
case
seriou
advers
effect
highli
desir
safeti
consider
bliznakov
vector
system
shut
withdraw
induc
drug
describ
use
doxycyclin
induc
fechner
et
al
srour
et
al
chtarto
et
al
safeti
issu
inher
specif
vector
type
eg
inflammatori
respons
adenovir
vector
transient
howev
appear
clinic
signific
two
recent
cardiolog
clinic
trial
employ
intracoronari
inject
adenovir
vector
express
vegf
grine
et
al
hedman
et
al
previou
trial
year
raper
et
al
livertarget
gene
therapi
protocol
aim
treatment
ornithin
transcarboxylas
defici
use
vector
dose
three
order
magnitud
higher
recent
cardiolog
trial
highest
dose
use
therein
vector
particl
grine
et
al
wherea
former
liverdirect
studi
multiorgan
failur
death
occur
one
patient
receiv
highest
dose
particl
raper
et
al
tragic
event
prompt
thorough
addit
investig
lehrman
marshal
risk
adenovectormedi
gene
therapi
includ
seriou
advers
event
even
may
occur
rare
predispos
individu
high
vector
dose
survey
clinic
trial
cancer
patient
employ
intravascular
adenovir
vector
report
dose
accept
safeti
profil
reid
et
al
even
rare
seriou
side
effect
consid
unaccept
howev
nonmalign
diseas
safeti
aav
vectorbas
cardiac
gene
therapi
current
investig
phase
safeti
trial
mount
sinai
hospit
new
york
unpublish
data
respect
possibl
risk
specif
aav
vector
immunogen
low
compar
adenovector
sun
et
al
sun
et
al
anoth
possibl
risk
deduc
capac
wildtyp
aav
chromosom
integr
appear
lost
howev
recombin
aav
vector
use
gene
therapi
rutledg
russel
rutledg
et
al
miller
et
al
miller
et
al
recent
studi
search
possibl
chromosom
effect
aav
vector
integr
miller
et
al
deserv
particular
attent
recent
report
late
unexpect
occurr
leukemia
children
treat
retrovir
vector
sever
combin
immmunodefici
scid
success
correct
primari
genet
defect
kohn
et
al
wherea
retrovir
vector
use
scid
studi
integr
human
genom
random
site
wildtyp
aav
show
prefer
chromosom
miller
et
al
nakai
et
al
possibl
consequ
genom
integr
aav
vector
deserv
close
attent
year
sinc
retrovectorassoci
leukemia
occur
year
success
ex
vivo
gene
therapi
scid
retrovir
mediat
transfer
gene
cell
kohn
et
al
check
haceinbeyabina
et
al
step
cardiomyopathi
sinc
coxsackieviru
adenovirus
may
caus
acut
myocard
inflammatori
cardiomyopathi
isol
common
coxsackievirusadenovirusreceptor
car
provid
interest
new
target
molecular
antivir
therapi
wherea
mani
virus
show
high
mutat
rate
enabl
develop
escap
mutant
mutat
cellular
viru
receptor
far
less
like
report
antivir
efficaci
car
gene
silenc
short
hairpin
sh
rna
cardiacderiv
cell
line
primari
neonat
rat
cardiomyocyt
pncm
treatment
carshrnagener
vector
result
almost
complet
silenc
car
express
cell
pncm
cell
car
alreadi
silenc
h
transduct
carshrna
express
vector
pncm
car
downregul
becom
visibl
day
thereaft
car
knockout
result
strong
inhibit
infect
cell
pncm
adenoviru
infect
inhibit
cell
pncm
conclud
car
knockout
shrna
vector
promis
adenoviru
infect
cell
type
specif
car
silenc
vector
express
shrna
need
consid
antivir
approach
initi
cardiac
viral
infect
document
clinic
context
acut
myocard
coxsackieviru
first
viru
detect
condit
human
bowl
et
al
adenovirus
serotyp
later
describ
common
agent
myocard
children
bowl
et
al
systemat
screen
patient
dilat
cardiomyopathi
dcm
recent
reveal
rather
broad
spectrum
virus
may
also
chronic
persist
human
myocardium
et
al
therefor
assum
acut
cardiac
viral
infect
may
caus
acut
ill
also
chronic
heart
diseas
definit
elimin
heart
et
al
diseas
may
progress
termin
heart
failur
requir
heart
transplant
last
therapeut
option
rna
interfer
rnai
process
posttranscript
gene
silenc
mediat
doublestrand
rna
dsrna
introduct
doublestrand
small
interf
rna
sirna
vector
express
short
hairpin
rna
shrna
alreadi
success
use
inhibit
replic
multipl
virus
vitro
vivo
includ
respiratori
virus
bitko
et
al
hepat
b
carmona
et
al
weinberg
et
al
chen
et
al
c
virus
takigawa
et
al
human
herp
yoon
et
al
cytomegaloviru
wiebusch
et
al
sar
coronarviru
lu
et
al
hayafun
et
al
b
merl
et
al
werk
et
al
howev
effici
rnai
depend
exact
homolog
sirna
target
sequenc
singl
mismatch
suffici
abrog
silenc
rnai
sabariego
et
al
mani
rna
virus
encod
polymeras
enzym
lack
proof
read
abil
result
high
mutat
rate
thu
high
probabl
virus
rapidli
develop
resist
particular
sirna
viru
replic
incorpor
nucleotid
mutat
within
target
sequenc
sirna
furthermor
shown
hepat
c
viru
becom
resist
particular
sirna
sever
cycl
replic
incorpor
point
mutat
within
sirna
target
sequenc
wilson
richardson
similar
data
report
boden
et
al
boden
et
al
polioviru
infect
gitlin
et
al
therefor
therapeut
target
nonvari
virusbind
receptor
suscept
cell
host
cell
molecul
directli
indirectli
involv
viru
infect
interest
altern
target
viru
werk
et
al
murray
et
al
anderson
akkina
arrighi
et
al
gao
et
al
ping
et
al
kameoka
et
al
one
approach
type
show
downregul
attach
receptor
dcsign
significantli
inhibit
hiv
infect
dendrit
cell
dc
prevent
transfer
infecti
particl
dc
cell
arrighi
et
al
adenovirus
type
use
coxsackievirusadenovirusreceptor
car
infect
target
cell
either
viru
attach
adenovirus
viru
intern
bergelson
et
al
therefor
car
repres
attract
target
inhibit
cardiac
adenoviru
infect
shown
recent
suppress
car
rnai
result
inhibit
infect
werk
et
al
coyn
bergelson
studi
carri
cell
noncardiac
origin
chemic
synthes
sirna
use
inhibit
car
express
howev
therapeut
use
synthet
sirna
significantli
limit
rapid
degrad
target
cell
result
transient
gene
silenc
watanab
et
al
moreov
cell
cardiac
origin
difficult
transfect
chemic
synthes
sirna
even
vitro
problem
significantli
aggrav
vivo
despit
intens
effort
recent
year
system
target
organspecif
deliveri
sirna
remain
major
hurdl
vivo
applic
rnai
therefor
investig
antivir
potenti
car
gene
silenc
cell
cardiac
origin
use
newli
develop
adv
gener
shrna
murin
rat
car
shcar
shcar
treatment
cell
primari
neonat
rat
cardiomyocyt
pncm
led
almost
complet
silenc
car
gene
express
effici
inhibit
infect
effici
inhibit
adenoviru
infect
seen
pncm
studi
also
reveal
cell
typespecif
respons
cellular
car
protein
shcar
treatment
need
consid
import
determin
new
antivir
approach
vivo
investig
efficaci
car
silenc
inhibit
adenoviru
infect
cardiac
cell
gener
total
three
shrna
direct
extracellular
domain
mcar
splice
variant
bergelson
et
al
tomko
et
al
fig
follow
publish
sirna
select
criteria
reynold
et
al
dna
oligonucleotid
encod
shrna
clone
express
plasmid
control
murin
rna
polymeras
iii
promotor
test
efficaci
cotransfect
cell
plasmid
togeth
plasmid
express
recombin
transfect
control
plasmid
express
irrelev
shrna
use
determin
extent
recombin
downregul
total
cellular
rna
isol
h
transfect
northern
blot
hybrid
carri
experi
show
two
shrna
highli
effici
silenc
silenc
control
shrna
affect
neither
express
fig
analyz
specif
also
test
downregul
human
car
hcar
cotransfect
plasmid
express
recombin
solubl
hcar
none
mous
carspecif
shrna
influenc
human
carmrna
express
contrast
humanspecif
shrna
effici
silenc
hcarmrna
express
fig
consid
one
mismatch
three
mismatch
compar
hcarmrna
experi
indic
high
speciesspecif
select
mcarshrna
determin
optim
adv
dose
transduct
mous
cardiac
cell
first
transduc
cell
gfpexpress
marker
adv
moi
moi
gfp
express
seen
cell
wherea
cytotox
effect
observ
dose
escal
result
slight
increas
transduct
rate
fig
moi
higher
cytotox
effect
becam
evid
increas
apoptot
cell
reduct
cell
growth
cell
express
cell
surfac
shown
therefor
silenc
capac
new
fig
express
evalu
effici
investig
respect
express
cell
assess
amount
advgener
cell
transduc
moi
twentyfour
h
c
downregul
mcarmrna
express
cell
transduc
adshplbr
moi
mcarmrna
express
measur
realtim
rtpcr
indic
time
point
later
express
analyz
timeand
dosedepend
transcript
detect
fig
consequ
shrna
express
strong
downregul
observ
h
transduct
near
maxim
reduct
observ
moi
higher
dose
result
signific
downregul
fig
result
indic
moi
optim
transduct
sinc
dose
allow
strong
downregul
cell
cytotox
viral
vector
still
low
next
investig
protein
express
transduct
cell
moi
disrupt
preexist
membraneassoci
cell
trypsin
h
transduct
reseed
procedur
led
ablat
protein
cell
surfac
day
transduct
fig
contrast
control
cell
rapidli
reexpress
fig
two
day
treatment
cell
still
display
membraneassoci
immunoreact
fig
probabl
reflect
residu
domain
still
anchor
cell
membran
trypsin
day
transduct
immunoreact
disappear
cell
wherea
remain
perman
detect
control
cell
fig
interestingli
car
express
celltocel
contact
site
cell
suggest
observ
stabil
car
intact
monolay
determin
homophil
heterophil
car
interact
celltocel
contact
site
togeth
result
indic
treatment
effici
inhibit
de
novo
synthesi
antivir
effect
silenc
investig
respect
cellular
car
constitut
intern
receptor
purpos
first
investig
protect
efficaci
function
dose
moi
rang
use
trypsininvolv
experiment
procedur
describ
cell
infect
h
transduct
amount
new
gener
progeni
viru
determin
six
day
later
viru
plaqu
assay
clearli
demonstr
replic
cell
rather
low
frequenc
sinc
cytopathogen
effect
visibl
investig
period
expect
strongest
reduct
progeni
viru
product
observ
highest
dose
moi
nevertheless
moi
still
led
signific
inhibit
replic
respect
wherea
moi
show
signific
effect
fig
investig
whether
disrupt
preexist
car
affect
infect
treat
cell
trypsininvolv
experiment
procedur
describ
omit
trypsin
step
transduct
titer
progeni
viru
gener
day
infect
strongli
reduc
cell
irrespect
whether
membraneassoci
car
disrupt
trypsin
fig
experi
indic
inhibit
replic
cell
high
efficaci
moreov
proteolysi
membraneassoci
car
seem
affect
infect
car
also
involv
adenoviru
infect
attach
receptor
investig
longterm
efficaci
respect
inhibit
cell
trypsin
reseed
investig
use
polyclon
rabbitanticar
antibodi
direct
extracellular
domain
car
protein
becam
undetect
earli
day
transduct
wherea
control
protein
abundantli
express
b
detect
knockdown
indirect
immunofluoresc
cell
treat
express
detect
indirect
immunofluoresc
use
polyclon
rabbitantibodi
sollerbr
et
al
direct
car
variant
intracellular
siv
tail
mcar
variant
access
abundantli
express
whole
investig
period
day
transduct
cell
transduc
control
vector
lefthand
panel
contrast
visibl
low
level
day
transduct
becam
undetect
later
time
point
righthand
panel
cell
nuclei
stain
dapi
overlay
imag
shown
notabl
local
cellcel
contact
site
white
arrow
wherea
cell
membran
region
contact
cell
display
protein
yellow
arrow
express
detect
cell
use
polyclon
rabbitantibodi
direct
car
variant
intracellular
tvv
tail
mcar
variant
access
shown
fig
h
later
cell
trypsin
reseed
trypsin
medium
chang
without
trypsin
h
transduct
cell
infect
moi
five
six
day
later
cell
lyse
three
freezethaw
cycl
viru
titer
determin
plaqu
assay
hela
cell
lefthand
diagram
right
side
exampl
plaqu
assay
hela
cell
use
dilut
cell
lysat
control
vector
transduc
cell
adenoviru
infect
investig
whether
proteolysi
preexist
car
affect
adenoviru
infect
cell
transduc
versu
control
vector
moi
twentyfour
hour
later
cell
either
trypsin
reseed
medium
chang
treatment
without
trypsin
day
transduct
cell
infect
luciferas
marker
adenoviru
moi
measur
luciferas
activ
h
later
reveal
persist
reduct
marker
gene
express
cell
investig
period
clearli
demonstr
carshrna
treatment
inhibit
adenoviru
uptak
cell
markedli
less
effici
inhibit
adenoviru
infect
close
similar
trypsin
nontrypsin
cell
fig
indic
proteolysi
car
affect
function
car
adenoviru
infect
fig
two
three
four
five
day
transduct
cell
infect
luciferas
marker
adenoviru
moi
luciferas
express
measur
h
b
inhibit
adenoviru
infect
without
trypsiin
cell
transduc
control
vector
adshplbr
moi
medium
chang
h
two
three
four
five
day
transduct
cell
infect
luciferas
marker
adenoviru
moi
luciferas
express
measur
h
later
cell
repres
perman
tumor
cell
line
heart
also
interest
investig
effect
car
silenc
onto
viral
infect
primari
cardiac
cell
reason
pncm
transduc
shrna
sequenc
complet
match
mous
rat
car
sequenc
control
vector
adshgfp
moi
dose
nearli
pncm
transduc
adv
result
shown
close
similar
cell
follow
treatment
pncm
car
express
unaffect
day
transduct
becom
strongli
downregul
day
day
transduct
fig
consequ
delay
car
downregul
challeng
pncm
moi
result
delay
inhibit
replic
fact
signific
reduct
replic
seen
pncm
infect
day
day
transduct
moreov
inhibit
replic
strongli
depend
initi
use
dose
moi
result
reduct
titer
moi
result
reduct
titer
day
respect
fig
similar
result
obtain
moi
transduc
pncm
infect
adv
adenoviru
uptak
reduc
day
day
transduct
effect
seen
day
fig
adenovirus
common
agent
acut
myocard
inflammatori
cardiomyopathi
bowl
et
al
et
al
although
treatment
potenti
elimin
cardiotrop
virus
improv
heart
function
patient
myocardi
persist
viral
genom
et
al
specif
treatment
adenoviru
infect
avail
date
respect
antivir
therapi
rnai
promis
new
technolog
therapeut
potenti
viral
infect
demonstr
multipl
vitro
vivo
studi
bitko
et
al
mccaffrey
et
al
carmona
et
al
park
et
al
merl
et
al
werk
et
al
despit
encourag
result
howev
sever
report
reveal
fundament
gener
problem
sirnabas
antivir
therapi
due
requir
strict
sequencespecif
therapeut
sirna
target
mrna
even
singl
point
mutat
viral
target
sequenc
may
result
rapid
select
escap
mutant
persist
viral
infect
wilson
richardson
boden
et
al
gitlin
et
al
studi
show
inhibit
adenoviru
infect
possibl
via
silenc
car
receptor
mean
vectorgener
carshrna
strategi
attract
altern
sirnabas
silenc
virusencod
gene
sinc
drastic
reduc
probabl
escap
mutant
develop
arrighi
et
al
contrast
previou
work
werk
et
al
investig
carri
myocardi
cell
repres
actual
target
adenoviru
infect
acut
myocard
inflammatori
cardiomyopathi
kandolf
bergelson
et
al
intern
occur
integrin
tomko
et
al
wickham
et
al
li
et
al
other
shown
heparan
sulfat
glycosaminoglycan
mhc
class
molecul
may
also
involv
bind
adenoviru
hong
et
al
dechecchi
et
al
moreov
express
receptor
involv
adenoviru
infect
highli
variabl
differ
cell
type
tissu
fechner
et
al
thu
variabl
receptor
express
level
interact
adenovirus
cell
type
specif
express
altern
receptor
like
explan
failur
complet
car
silenc
achiev
effici
blockad
adenoviru
infect
cell
enhanc
efficaci
inhibit
adenoviru
infect
via
antireceptor
approach
therefor
seem
necessari
simultan
inhibit
car
coreceptor
contrast
antiadenoviru
experi
anticar
approach
effici
respect
cell
pncm
magnitud
inhibit
infect
correl
well
vectorinduc
ablat
mcar
cell
surfac
emphas
key
role
car
infect
cardiac
cell
molecular
reason
differ
anticar
treatment
adenoviru
versu
infect
may
due
uniqu
role
play
car
infect
induc
conform
chang
viru
capsid
essenti
entri
target
cell
coyn
bergelson
high
efficaci
shcar
vector
viru
indic
car
silenc
promis
therapeut
approach
infect
myocardium
previou
studi
shown
similar
degre
inhibit
use
sirna
direct
viral
genom
rna
rna
intermedi
merl
et
al
werk
et
al
yuan
et
al
combin
direct
antivir
approach
prone
escap
mutant
develop
current
antireceptor
strategi
like
increas
efficaci
rnaibas
antivir
therapi
recent
shown
silenc
car
chemic
synthetis
sirna
inhibit
infect
human
cell
noncardiac
origin
werk
et
al
howev
approach
decreas
viru
titer
markedli
less
present
studi
employ
advgener
shcar
differ
result
high
transduct
efficaci
adv
prolong
highlevel
express
shcar
bottleneck
chemic
synthes
sirna
transient
silenc
activ
day
cardiac
cell
watanab
et
al
viral
vector
express
shrna
howev
enabl
long
term
silenc
target
gene
cell
cardiac
origin
fechner
et
al
allow
effici
deliveri
transgen
sequenc
heart
wang
et
al
pseudotyp
vector
seem
promis
vector
cardiac
gene
transfer
enabl
highli
effici
transduct
heart
use
simpl
intraven
applic
rout
pacak
et
al
inagaki
et
al
car
cell
adhes
protein
mediat
homotyp
cohen
et
al
honda
et
al
heterotyp
zen
et
al
intercellular
interact
compon
special
intercellular
junction
includ
epitheli
tight
junction
cohen
et
al
neuromuscular
junction
shaw
et
al
myocardi
intercal
disc
noutsia
et
al
found
local
exclus
celltocel
contact
site
cell
possibl
consequ
cell
membraneassoci
car
stabil
homotyp
carcar
heterotyp
carprotein
intercellular
protein
interact
contrast
previou
car
silenc
attempt
use
synthet
sirna
newli
develop
viral
vector
achiev
near
complet
stabl
knockout
car
essenti
prerequisit
reveal
significantli
differ
kinet
car
protein
ablat
differ
cell
type
particular
unexpectedli
high
stabil
car
primari
cell
versu
stabl
cell
line
data
may
explain
cell
typespecif
car
protein
kinet
differ
car
mrna
stabil
process
carshrna
rna
interfer
machineri
also
taken
account
delay
downregul
car
follow
vectormedi
carshrna
deliveri
primari
cardiomyocyt
relev
vivo
investig
sinc
time
lag
vector
applic
car
silenc
need
taken
consider
antivir
therapi
studi
one
import
concern
associ
downregul
cellular
receptor
molecul
antivir
therapi
possibl
side
effect
result
ablat
normal
cellular
function
receptor
organogenesi
car
highli
express
heart
rapidli
downregul
post
partum
fechner
et
al
recent
publish
genom
mous
knockout
model
cardiomyocytespecif
car
delet
result
sever
cardiac
anomali
death
day
embryon
develop
chen
et
al
dorner
et
al
car
gene
becam
ablat
late
embryon
develop
howev
cardefici
anim
surviv
adulthood
evid
cardiac
anomali
chen
et
al
find
suggest
car
silenc
rnai
employ
studi
well
toler
consider
period
time
viru
migrat
spread
effici
inhibit
furthermor
treatment
cell
advgener
shcar
reveal
side
effect
sinc
found
chang
cell
growth
cell
morpholog
factin
cytoskeleton
protein
express
shown
howev
car
integr
compon
tight
junction
may
play
import
role
cell
methabol
sever
tissu
organ
experi
confirm
shrnamedi
car
knockdown
undesir
side
effect
vivo
summari
high
efficaci
car
gene
silenc
shrna
cardiacderiv
cell
observ
variabl
result
obtain
adenovirus
contrast
previou
silenc
attempt
use
sirna
shrnaplasmid
newli
develop
shrnavector
abl
achiev
near
complet
stabl
knockout
car
transcript
turn
reveal
significantli
differ
respons
cellular
car
protein
carshrna
treatment
need
consid
import
determin
new
antivir
approach
vivo
heart
failur
impair
function
phospholamban
plb
regul
sarcoplasm
reticulum
sr
ca
pump
contribut
cardiac
dysfunct
heart
failur
hf
plb
downregul
may
increas
activ
improv
cardiac
function
small
interf
si
rna
mediat
effici
gene
silenc
rna
interfer
rnai
howev
use
vivo
gene
therapi
limit
sirna
instabl
plasma
tissu
low
sirna
transfer
rate
target
cell
address
problem
develop
adenovir
vector
adv
transcrib
short
hairpin
sh
rna
rat
plb
evalu
potenti
silenc
plb
gene
modul
ca
sequestr
primari
neonat
rat
cardiomyocyt
pncm
period
day
vector
transduct
result
stabl
ablat
plbmrna
moi
plb
protein
gradual
decreas
day
left
wherea
serca
na
ca
exchang
calsequestrin
troponin
tni
protein
remain
unchang
plb
silenc
associ
mark
increas
atpdepend
oxalatesupport
ca
uptak
free
ca
rapid
loss
respons
pkadepend
stimul
ca
uptak
maintain
day
summari
result
indic
advderiv
plbshrna
mediat
highli
effici
specif
stabl
plb
gene
silenc
modul
activ
ca
sequestr
pncm
avail
new
vector
enabl
employ
rnai
treatment
hf
vivo
heart
failur
hf
remain
lead
caus
mortal
develop
world
deterior
function
fail
heart
partial
attribut
dysfunct
plbcontrol
piacentino
et
al
reduct
express
plb
phosphoryl
wolska
et
al
schmidt
et
al
may
contribut
dysfunct
nonphosphoryl
plb
keep
ca
affin
low
result
decreas
sr
ca
uptak
slow
relax
decreas
sr
ca
load
plb
phosphoryl
respons
stimul
reliev
inhibit
germlin
transgen
approach
ablat
plb
express
function
mice
luo
et
al
somat
gene
transfer
domin
neg
plb
mutant
iwanaga
et
al
hoshijima
et
al
plbantisenserna
eizema
et
al
li
et
al
et
al
delmont
et
al
intracellular
inhibitori
plb
antibodi
dieterl
et
al
meyer
et
al
employ
increas
cardiac
sr
ca
transport
activ
henc
contractil
function
cardiomyocyt
physiolog
diseas
condit
rna
interfer
rnai
mediat
chemic
synthes
sirna
recent
employ
silenc
plb
express
cardiomyocyt
watanab
et
al
rnai
reli
posttrancript
sequencespecif
gene
silenc
via
small
homolog
doublestrand
rna
leung
whittak
silenc
efficaci
higher
antisens
rna
ogorelkova
et
al
nevertheless
therapeut
use
synthet
sirna
significantli
limit
rapid
degrad
target
cell
result
transient
gene
silenc
watanab
et
al
difficulti
achiev
suffici
transfer
rate
multipl
cell
therapeut
interest
includ
cardiomyocyt
limit
significantli
aggrav
vivo
despit
intens
effort
recent
year
system
deliveri
sirna
remain
major
hurdl
vivo
applic
rnai
lewi
et
al
sinc
viral
vector
system
shown
suitabl
overcom
limit
vitro
vivo
develop
novel
adenovir
vector
adv
suitabl
transcript
shrna
target
plb
treatment
vector
result
highli
effici
specif
plb
gene
silenc
primari
neonat
rat
cardiac
myocyt
pncm
stabl
week
associ
mark
increas
sr
ca
sequestr
order
select
potenti
plbsirna
sequenc
gener
plbshrna
initi
cotransfect
cell
gfprat
plb
fusion
construct
plu
differ
sirna
direct
rat
plb
among
five
test
sirna
three
highli
effici
downregul
fusion
transcript
effici
sirna
clone
shrna
express
plasmid
dna
sequenc
encod
plbshrna
cotransfect
experi
gfprat
plb
fusion
construct
show
high
efficaci
fig
base
result
construct
adv
design
adshplbr
gener
fig
assess
efficaci
vector
adshplbr
downregul
endogen
express
plb
actual
target
cell
transduc
primari
neonat
rat
cardiomyocyt
pncm
adshplbr
investig
doseand
timedepend
action
control
adv
gener
shrna
irrelev
plb
cardiac
ca
metabol
employ
test
target
specif
adshplbr
treatment
pncm
adshplbr
result
strong
dosedepend
downregul
plbmrna
express
moi
moi
day
transduct
fig
rapid
strong
endur
plb
silenc
observ
treatment
pncm
adshplbr
moi
prolong
investig
period
plbmrna
abund
extrem
low
baselin
quantit
realtimertpcr
shown
earli
day
remain
level
day
end
experi
contrast
plbmrna
express
stay
baselin
level
nontransduc
control
pncm
fig
similar
delay
chang
occur
plb
protein
level
decreas
plb
protein
becam
first
visibl
day
remain
compar
control
plb
protein
decreas
continu
day
remain
contrast
protein
level
tni
remain
unchang
indic
absenc
unspecif
side
effect
cardiac
protein
confirm
equal
load
sampl
membran
strip
reprob
monoclon
antibodi
actin
note
synthet
sirna
direct
vanilloid
receptor
lower
dosedepend
action
cell
cotransfect
pplbgfp
indic
immunoblot
carri
h
transfect
describ
vector
shrna
gener
fig
examin
function
consequ
plbshrnainduc
declin
plb
protein
level
pncm
transduc
adshplbr
control
vector
moi
cell
homogen
sr
ca
uptak
rate
determin
submicromolar
satur
free
ca
concentr
latter
sr
ca
atpas
known
insensit
nonphosphoryl
plb
wherea
submicromolar
ca
nonphosphoryl
plb
shown
decreas
ca
affin
enzym
rate
ca
uptak
determin
free
ca
normal
maximum
uptak
rate
vmax
valu
satur
ca
rel
ca
uptak
rate
differ
nontransduc
adshplbrtreat
pncm
one
day
transduct
day
approxim
vmax
rel
ca
uptak
rate
remain
level
nontransduc
pncm
day
transduct
contrast
increas
steadili
adshplbrtransduc
pncm
reach
vmax
day
transduct
remain
high
level
end
experi
day
fig
indic
increas
ca
affin
sr
ca
atpas
plbdefici
pncm
shown
fig
linear
relationship
rel
rate
ca
uptak
respect
rel
plb
protein
level
observ
adshplbrtransduc
pncm
addit
investig
degre
stimul
ca
uptak
protein
kinas
pka
depend
vitro
phosphoryl
follow
transduct
pncm
adshplbr
moi
day
transduct
pkainduc
increas
rate
ca
uptak
fig
timedepend
adshplbrmedi
plb
protein
downregul
western
blot
analysi
plb
protein
express
pncm
transduc
adshplbr
control
vector
moi
cell
harvest
indic
time
point
transduct
westernblot
carri
signific
plb
downregul
becam
visibl
day
posttransduct
express
level
serca
tni
unaffect
investig
period
b
rel
express
level
plb
serca
tni
protein
normal
respect
western
blot
signal
correspond
time
point
control
vectortransduc
pncm
nontransduc
adshplbrtransduc
pncm
homogen
adshplbrtransduc
pncm
pka
stimul
becam
complet
lost
around
day
transduct
wherea
approxim
stimul
ca
uptak
observ
day
nontransduc
pncm
fig
fig
demonstr
highli
effici
specif
ablat
endogen
plb
express
pncm
plbshrna
express
adv
shrna
transcript
result
downregul
endogen
plbmrna
baselin
persist
day
chang
express
cardiac
protein
includ
ca
handl
protein
occur
indic
high
target
specif
plbshrna
vector
control
vector
effect
plb
indic
absenc
unspecif
effect
shrna
per
se
pncm
function
level
ca
affin
markedli
increas
plb
silenc
accompani
loss
respons
pkadepend
stimul
ca
uptak
plb
form
function
complex
regul
ca
uptak
alter
level
either
protein
may
therefor
profound
effect
chang
plb
ratio
therebi
alter
intracardiac
ca
homeostasi
demonstr
normal
diseas
heart
use
transgen
anim
model
gene
transfer
approch
target
plb
iwanaga
et
al
delmont
et
al
vetter
et
al
miyamoto
et
al
reduct
ratio
achiev
classic
overexpress
cdna
encod
domin
neg
pl
mutant
plbtarget
antibodi
other
employ
antisens
rna
direct
plbmrna
eizema
et
al
et
al
contrast
rnaibas
therapeut
strategi
yet
wide
employ
cardiovascular
field
synthet
sirna
recent
employ
downregul
valu
presenc
ad
pka
normal
measur
presenc
synthet
pka
peptid
inhibitor
shown
mean
sd
four
separ
transduct
control
nontransduc
cell
plb
cardiomyocyt
watanab
et
al
sinc
sirna
enabl
transient
gene
silenc
develop
adv
gener
shrna
mediat
effici
specif
stabl
plb
silenc
respect
durat
silenc
strike
differ
previou
work
use
synthet
sirna
watanab
et
al
current
advbas
approach
observ
sirna
result
downregul
plbmrna
baselin
within
h
effect
almost
complet
lost
day
contrast
plbmrna
level
remain
baselin
period
plbshrnaadv
treatment
vectorbas
shrna
gener
clearli
superior
synthet
sirna
respect
silenc
stabil
respect
efficaci
silenc
plbshrnaadv
result
ablat
plbmrna
wherea
former
studi
use
plbantisensernaadv
achiev
maxim
plbmrna
ablat
eizema
et
al
line
previou
report
found
plb
ablat
improv
depend
intracellular
ca
handl
signific
upregul
ca
affin
first
observ
plb
protein
baselin
interestingli
plb
downregul
suffici
mediat
maxim
increas
ca
affin
reduct
addit
effect
steadi
loss
respons
pkadepend
ca
uptak
stimul
plbshrna
complet
loss
respons
observ
day
loss
respons
pkadepend
ca
uptak
stimul
control
group
indic
rnaimedi
plb
silenc
link
anticip
loss
respons
sr
ca
transport
system
pkadepend
phosphoryl
normal
mediat
plb
although
rnai
power
method
gene
silenc
implement
therapeut
purpos
human
requir
two
technic
problem
solv
first
instabl
chemic
synthes
sirna
plasma
cell
requir
repetit
administr
vivo
loss
initi
effici
target
gene
silenc
cardiomyocyt
within
day
allow
estim
requir
sirna
applic
frequenc
specif
target
tissu
problem
may
overcom
viral
vector
system
produc
shrna
long
time
period
vivo
intermedi
stabil
advshrna
system
use
may
suffic
even
provid
advantag
longterm
stabl
aav
vector
wang
et
al
minamisawa
et
al
b
rnai
effect
need
temporarili
acut
potenti
revers
condit
eg
heart
failur
due
viral
autoimmun
myocard
second
cardiac
target
synthet
sirna
current
possibl
experiment
method
unsuit
possibl
transfer
clinic
set
lewi
et
al
contrast
recent
develop
vector
technolog
eg
pseudotyp
aav
cardiotrop
properti
like
allow
cardiac
target
transgen
shrna
express
cassett
simpl
intraven
inject
inagaki
et
al
pacak
et
al
importantli
small
express
cassett
specif
plbshrna
sequenc
use
studi
easili
incorpor
differ
aav
vector
select
purpos
within
framework
proofofconcept
studi
introduc
novel
plshrna
tool
perform
vivo
work
sinc
efficaci
plb
ablat
heart
failur
therapi
anim
model
alreadi
demonstr
iwanaga
et
al
delmont
et
al
vetter
et
al
miyamoto
et
al
futur
cardiac
gene
therapi
studi
use
pseudotyp
vector
sinc
two
recent
studi
inagaki
et
al
pacak
et
al
demonstr
import
advantag
pseudotyp
lentivirus
adenovirus
previous
use
aav
vector
one
remain
challeng
modif
cassett
way
allow
exogen
regulat
shrna
express
adjust
degre
plb
modul
chang
physiolog
condit
appear
particularli
import
human
sinc
chronic
plb
defici
due
genom
mutat
associ
cardiomyopathi
schmitt
et
al
zhao
et
al
haghighi
et
al
haghighi
et
al
wherea
mice
complet
knockout
plb
may
also
achiev
rnai
abl
rescu
sever
cardiomyopath
phenotyp
mlp
knockout
mice
minamisawa
b
suggest
unregul
plb
silenc
appropri
speci
applic
human
probabl
requir
regulat
rnai
recent
studi
group
extend
repertoir
rnai
vector
suppress
plb
seri
vector
longterm
vivo
studi
origin
adv
describ
analog
vector
demonstr
period
month
adv
vector
month
vector
rnai
vector
significantli
improv
systol
diastol
cardiac
function
reduc
cardiac
hypertrophi
dilat
improv
surviv
case
aav
vector
unpublish
data
furthermor
catecholamineinduc
deregul
sever
function
relev
mirna
cardiomyocyt
restor
normal
rnai
vector
treatment
unpublish
data
past
decad
molecular
structur
foundat
key
problem
associ
cardiac
gene
therapi
therebi
also
mani
encount
regulatori
rnabas
approach
defin
consider
detail
becom
obviou
effici
select
transport
regulatori
rna
cdna
vector
myocardium
target
first
key
issu
major
problem
futur
clinic
cardiac
rna
gene
therapi
protocol
probabl
involv
direct
intracoronari
vector
infus
achiev
target
select
level
target
may
enhanc
use
cardiacspecif
promotor
result
confin
regulatori
rna
cdna
express
level
ii
importantli
regulatori
rna
eg
shrna
transcript
common
tissuespecif
type
ii
polymeras
promot
use
sinc
proper
shrna
transcript
recent
achiev
type
iii
promot
none
tissuespecif
problem
may
overcom
howev
introduct
micrornabas
shrna
express
system
also
allow
use
cardiacspecif
drugregulat
type
ii
polymeras
promotor
make
level
ii
target
also
avail
regulatori
rnabas
therapi
anoth
major
breakthrough
field
cardiac
rna
gene
therapi
discoveri
certain
pseudotyp
aav
vector
particular
deriv
thereof
cardiotrop
even
simpl
intraven
inject
level
iii
target
although
yet
absolut
cardiacspecif
also
reach
liver
intraven
rout
modif
aav
capsid
may
solv
allevi
issu
current
use
combin
level
ii
target
alreadi
enabl
highli
cardiacspecif
rna
gene
therapi
protocol
one
evalu
first
clinic
trial
depend
target
diseas
therapeut
goal
may
achiev
regulatori
rna
transgen
express
day
week
requir
longterm
even
lifelong
stabil
current
avail
adenovector
capabl
achiev
shortterm
goal
may
also
suffic
bridgetorecoveri
bridgetotranspl
situat
nevertheless
even
shortterm
therapi
gener
better
safeti
profil
aav
vector
lead
use
vector
type
clinic
rna
gene
therapi
protocol
longterm
therapi
aav
vector
priori
system
choic
due
impress
longterm
cardiac
stabil
function
sever
experiment
studi
wherea
control
transgen
express
avail
year
via
drugregulat
system
goal
recent
achiev
regulatori
rna
therapi
convent
gene
therapi
optim
clinic
rna
therapi
protocol
also
like
involv
drugregulat
system
sinc
certain
condit
shrna
like
also
regulatori
rna
eg
mirna
shown
seriou
advers
effect
option
shut
express
therefor
significantli
add
therapeut
safeti
clinic
set
even
basic
issu
solv
satisfactorili
intens
effort
establish
regulatori
rna
gene
therapeut
regim
clinic
critic
influenc
four
determin
first
specif
therapeut
target
access
mean
eg
convent
pharmacotherapi
second
target
diseas
suffici
sever
justifi
effort
risk
experiment
therapeut
approach
third
number
patient
may
possibl
benefit
experiment
therapi
establish
rel
high
sinc
greatli
facilit
fundrais
incorpor
industri
partner
fourth
therapeut
protocol
address
pathomechan
eg
disturb
cardiac
ca
homeostasi
common
cardiac
diseas
divers
etiolog
broader
rang
applic
strategi
target
specif
pathogen
step
need
tailormad
everi
differ
type
pathogenesi
without
doubt
cardiovascular
medicin
gener
specif
field
cardiomyopathi
heart
failur
larg
number
patient
urgent
need
improv
treatment
first
regulatori
rna
gene
therapeut
protocol
adequ
fulfil
criteria
thu
actual
clinic
translat
first
therapi
type
like
occur
within
next
decad
